The University of Chicago Header Logo

Connection

Arlene Chapman to Treatment Outcome

Back to Details
This is a "connection" page, showing publications Arlene Chapman has written about Treatment Outcome.
Arlene Chapman
Connection Strength
0.769
Treatment Outcome
  1. Hypertensive APOL1 risk allele carriers demonstrate greater blood pressure reduction with angiotensin receptor blockade compared to low risk carriers. PLoS One. 2019; 14(9):e0221957.
    View in: PubMed
    Score: 0.073
  2. Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/ß-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials. J Am Heart Assoc. 2017 Nov 02; 6(11).
    View in: PubMed
    Score: 0.064
  3. Renal volume in children with ADPKD: size matters. Clin J Am Soc Nephrol. 2009 Apr; 4(4):698-9.
    View in: PubMed
    Score: 0.035
  4. Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis. Clin J Am Soc Nephrol. 2009 Mar; 4(3):560-6.
    View in: PubMed
    Score: 0.035
  5. Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies. Clin J Am Soc Nephrol. 2008 Jul; 3(4):1197-204.
    View in: PubMed
    Score: 0.034
  6. Treatment of autosomal dominant polycystic kidney disease (ADPKD): the new horizon for children with ADPKD. Pediatr Nephrol. 2008 Jul; 23(7):1029-36.
    View in: PubMed
    Score: 0.033
  7. Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension. Am J Hypertens. 2008 Jan; 21(1):61-6.
    View in: PubMed
    Score: 0.032
  8. Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome. Am J Nephrol. 2021; 52(3):180-189.
    View in: PubMed
    Score: 0.020
  9. Genome-Wide Meta-Analysis of Blood Pressure Response to ß1-Blockers: Results From ICAPS (International Consortium of Antihypertensive Pharmacogenomics Studies). J Am Heart Assoc. 2019 08 20; 8(16):e013115.
    View in: PubMed
    Score: 0.018
  10. Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension. Am J Hypertens. 2019 06 11; 32(7):668-675.
    View in: PubMed
    Score: 0.018
  11. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. Kidney Int. 2019 07; 96(1):159-169.
    View in: PubMed
    Score: 0.018
  12. A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan. J Am Soc Nephrol. 2018 10; 29(10):2458-2470.
    View in: PubMed
    Score: 0.017
  13. Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses). Circ Genom Precis Med. 2018 04; 11(4):e001854.
    View in: PubMed
    Score: 0.016
  14. Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade? Curr Hypertens Rev. 2018; 14(1):39-47.
    View in: PubMed
    Score: 0.016
  15. Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics. J Am Heart Assoc. 2017 12 29; 7(1).
    View in: PubMed
    Score: 0.016
  16. Standardised Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease. Trials. 2017 Nov 23; 18(1):560.
    View in: PubMed
    Score: 0.016
  17. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial. Nephrol Dial Transplant. 2017 Nov 01; 32(11):1857-1865.
    View in: PubMed
    Score: 0.016
  18. Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease. Am J Nephrol. 2017; 45(3):257-266.
    View in: PubMed
    Score: 0.015
  19. Genome-Wide Prioritization and Transcriptomics Reveal Novel Signatures Associated With Thiazide Diuretics Blood Pressure Response. Circ Cardiovasc Genet. 2017 Jan; 10(1).
    View in: PubMed
    Score: 0.015
  20. Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials. Curr Hypertens Rev. 2017; 13(2):109-120.
    View in: PubMed
    Score: 0.015
  21. Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. Kidney Int. 2017 02; 91(2):493-500.
    View in: PubMed
    Score: 0.015
  22. Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial. J Am Soc Nephrol. 2017 May; 28(5):1592-1602.
    View in: PubMed
    Score: 0.015
  23. A Genetic Response Score for Hydrochlorothiazide Use: Insights From Genomics and Metabolomics Integration. Hypertension. 2016 09; 68(3):621-9.
    View in: PubMed
    Score: 0.015
  24. Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial. Nephrol Dial Transplant. 2016 11; 31(11):1887-1894.
    View in: PubMed
    Score: 0.014
  25. Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC). Am J Kidney Dis. 2015 Oct; 66(4):583-90.
    View in: PubMed
    Score: 0.014
  26. Pharmacogenomics of hypertension: a genome-wide, placebo-controlled cross-over study, using four classes of antihypertensive drugs. J Am Heart Assoc. 2015 Jan 26; 4(1):e001521.
    View in: PubMed
    Score: 0.013
  27. Baseline predictors of central aortic blood pressure: a PEAR substudy. J Am Soc Hypertens. 2014 Mar; 8(3):152-8.
    View in: PubMed
    Score: 0.012
  28. The role of plasma renin activity, age, and race in selecting effective initial drug therapy for hypertension. Am J Hypertens. 2013 Aug; 26(8):957-64.
    View in: PubMed
    Score: 0.012
  29. Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics. J Hypertens. 2013 Apr; 31(4):698-704.
    View in: PubMed
    Score: 0.012
  30. G protein receptor kinase 4 polymorphisms: ß-blocker pharmacogenetics and treatment-related outcomes in hypertension. Hypertension. 2012 Oct; 60(4):957-64.
    View in: PubMed
    Score: 0.011
  31. Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide. J Transl Med. 2012 Mar 22; 10:56.
    View in: PubMed
    Score: 0.011
  32. Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response. J Transl Med. 2012 Mar 13; 10:47.
    View in: PubMed
    Score: 0.011
  33. Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney Int. 2012 Mar; 81(6):577-85.
    View in: PubMed
    Score: 0.011
  34. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin J Am Soc Nephrol. 2011 Oct; 6(10):2499-507.
    View in: PubMed
    Score: 0.010
  35. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Am J Kidney Dis. 2011 May; 57(5):692-9.
    View in: PubMed
    Score: 0.010
  36. Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. Pharmacogenet Genomics. 2011 Jan; 21(1):42-9.
    View in: PubMed
    Score: 0.010
  37. Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens. 2010 Sep; 23(9):1014-22.
    View in: PubMed
    Score: 0.010
  38. Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clin J Am Soc Nephrol. 2010 Jul; 5(7):1312-29.
    View in: PubMed
    Score: 0.010
  39. Comparison of office, ambulatory, and home blood pressure antihypertensive response to atenolol and hydrochlorthiazide. J Clin Hypertens (Greenwich). 2010 Jan; 12(1):14-21.
    View in: PubMed
    Score: 0.009
  40. Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension. 2008 Aug; 52(2):359-65.
    View in: PubMed
    Score: 0.008
  41. Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjects. Am J Hypertens. 2005 Aug; 18(8):1077-83.
    View in: PubMed
    Score: 0.007
  42. Reproducibility of blood pressure response to hydrochlorothiazide. J Clin Hypertens (Greenwich). 2002 Nov-Dec; 4(6):408-12.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.